Q-omics provides the consensus-scored PPP5D1 profile across patient tissues and cancer cell-line models. PPP5D1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, PPP5D1 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, PPP5D1 RNA expression shows 18,384 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight PAAD, LUAD, and THYM as cancer lineages where PPP5D1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP5D1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP5D1 survival associations across molecular data types. PPP5D1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP5D1 RNA expression–survival associations across cancer types. High PPP5D1 expression shows unfavorable associations in OV and SCLC, but favorable associations in PAAD, KIRC, CESC and KIRP. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify PAAD as the clearest survival context for PPP5D1 RNA expression.
This table summarizes PPP5D1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PPP5D1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP5D1 shows lower tumor expression in LUAD, THCA, LUSC, BLCA, KICH and UCEC. The LUAD box plot shows higher PPP5D1 RNA expression in normal versus tumor tissue (log2 FC = −0.448, t-test p < 0.001).
This table shows molecular features associated with PPP5D1 in patient tissues and cancer cell lines. In patient samples, PPP5D1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP5D1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
